Short hairpin RNAs (shRNAs) are effective in generating stable repression of gene expression. RNA polymerase III (RNAP III) type III promoters (U6 or H1) are typically used to drive shRNA expression. While useful for some knockdown applications, the robust expression of U6/H1-driven shRNAs can induce toxicity and generate heterogeneous small RNAs with undesirable off-target effects. Additionally, the U6 and H1 promoters encompass the majority of the ~270 base pairs (bp) of vector space required for shRNA expression. This can limit the efficacy and/or number of delivery vector options, particularly when delivery of multiple gene/shRNA combinations is required. Here, we develop a compact shRNA (cshRNA) expression system based on retroviral microRNA (miRNA) gene architecture that uses RNAP III type II promoters. We demonstrate that cshRNAs coded from as little as 100 bps of total coding space can precisely generate small interfering RNAs (siRNAs) that are active in the RNA-induced silencing complex (RISC). We provide an algorithm with a user-friendly interface to design cshRNAs for desired target genes. This cshRNA expression system reduces the coding space required for shRNA expression by greater than two-fold as compared to the U6/H1 promoters, which may facilitate therapeutic RNAi applications where delivery vector space is limiting.
Introduction
RNA interference (RNAi) is a post-transcriptional mechanism for regulating gene expression in eukaryotes [for review see (1) ]. During RNA interference (RNAi) in mammals, small interfering RNAs (siRNAs; ~22 nts in length) guide the RNA-induced silencing complex (RISC) to mRNAs via base-pair complementarity. RISC association with mRNAs results in cleavage of the mRNA transcript by Argonaute 2 (Ago2), resulting in repression of gene expression (2) . The ability of engineered RNAi to specifically target almost any mRNA transcript is a potentially useful therapeutic agent for a broad spectrum of human diseases, including cancer, inflammatory diseases, neurodegenerative diseases, ocular diseases, and viral infections (3) (4) (5) (6) . However, strategies for successful implementation of therapeutic RNAi in humans continue to be refined.
To achieve RNAi, small double-stranded RNAs (~22 nts in length) need to be delivered to or generated in the cytosol of the target cell. This can be accomplished via transfection of synthetic siRNAs into cells, or by transfection or transduction of DNA templates that express siRNA-generating RNAs (6) . One advantage of siRNA generation from a DNA template [e.g., lentiviruses, plasmids, Adeno-associated virus (AAV) vectors, PCR amplicons, and small circular DNAs (coligos)] is the potential for stable longterm RNAi (6, 7) . A common method to achieve this is through expression of short hairpin RNAs (shRNAs), which are processed by the RNase III enzyme Dicer into siRNAs. Typically, the U6 or H1 promoters/enhancers (RNAP III class III) are used to promote RNAP III-mediated transcription of the shRNA (8, 9) . These promoters are located entirely upstream of the transcription initiation site and promote robust shRNA expression. This makes design of the downstream shRNA straightforward and modular, while ensuring consistent and robust shRNA expression. However, the upstream U6/H1 promoters (215, 246 bps respectively) encompass >80% of the genomic template space required for expression of a shRNA. Additionally, the robust shRNA expression promoted by the U6/H1 promoters can result in cytotoxicity by saturating factors required for generating endogenous microRNAs (miRNAs). Furthermore, these shRNA vectors often give rise to abundant small RNAs with heterogeneous 5' ends that can increase undesirable off-target effects on unintended mRNA targets (10, 11) . Thus, alternative shRNA expression strategies may offer advantages over the conventional U6/H1-driven shRNA for in vivo applications whereby smaller templates, less robust expression, and more precise biogenesis are important.
Bovine leukemia virus (BLV) expresses five pre-miRNAs from ~550 bps of genomic space (12) . Each pre-miRNA is directly transcribed by RNAP III from individual compact RNAP III type II genes (13) (14) (15) . This is analogous to typical shRNA generation, but unlike the U6/H1 promoters, the two cis promoter elements (the A and B boxes) that promote RNAP III transcription initiation are located within or directly downstream of the pre-miRNA hairpin (13, 16, 17) . This architecture requires as little as 80-bps of template space to encode for the pre-miRNA and promoter elements. Further, BLV pre-miRNA expression appears to be less robust in comparison to U6/H1-driven shRNAs, which may account for the lack of noticeable cytotoxicity accompanied with BLV pre-miRNA expression (12, 13) . This attribute of BLV pre-miRNA expression is likely important, since cytotoxicity during BLV persistence in vivo would be disadvantageous to viral fitness.
Here, we develop an shRNA expression system based on the design principles gleaned from the architecture of the BLV miRNA genes. We demonstrate the efficacy of these BLV-based compact shRNA cassettes (cshRNAs) by designing multiple cshRNAs and evaluating their expression and RNAi activity against three different target transcripts. This work provides a method to express shRNAgenerated siRNAs with defined termini from a coding sequence of 100 bps, which may be useful for RNAi-based therapies and laboratory applications where smaller gene silencing expression cassettes are desirable.
Materials and Methods

Plasmids
The pBLV-B1 vector is described in (13) . To generate the 115-bp and 100-bp BLV-B1 templates, the 115-bp BLV-B1 sense primer or 100-bp BLV-B1 sense primer was used with the BLV-B1 antisense primer ( Supplementary Table S1 ) to generate the amplicons from the pBLV-B1 via PCR using Phusion polymerase (New England BioLabs). Amplicons were digested with Xho1/Xba1 and ligated into the Xho1/Xba1 sites of the pIDTSmart-kan (pISK), in which we previously engineered Xho1/Xba1 sites (12) .
Each cshRNA construct was generated by annealing sense and antisense oligonucleotides (Integrated DNA technologies; Supplementary Table S1 ) that encoded the cshRNA hairpin and ~15 nts of flanking sequence. Phusion polymerase was used to fill-in the single-stranded overhangs. The cshRNA-encoding fragments were then extended via PCR using the universal B1-flanking sense and antisense primers ( Supplementary Table S1 ) to add the ~40 bps of the BLV-B1 locus flanking the BLV-pre-miR-B1 hairpin and the Xho1 and Xba1 sites. The amplicons were then digested with Xho1/Xba1 and ligated into Xho1/Xba1 sites of the pIDT-smart-Kan (pISK). The RISC reports were made by extension of RISC reporter (RR) primers ( Supplementary Table S1 ) with Phusion polymerase. Amplicons were digested with Xho1/Xba1 and ligated into the Xho1/Xba1 sites of pcDNA3.1dsRluc (18) . For the p53-and pRb-3'-UTR reporters, the p53-and pRb-3'UTRs were amplified using Phusion polymerase and the p53-and Rb-3'UTR primers ( Supplementary Table S1 ) from cDNA prepared from HEK293T RNA using Superscript III reverse transcriptase (Invitrogen) and polyT 20 primer. The amplicons were digested with Spe1/Sal1 and ligated into the Xho1/Xba1 sites of pcDNA3.1dsRluc (Addgene plasmid # 68053). All plasmids were sequence verified by ICMB core facilities (The University of Texas at Austin).
Cell culture
HEK293T and HEK293 cells were obtained from ATCC. Cells were maintained in DMEM supplemented with FBS (Cellgro; 10% vol/vol). Transfections were performed using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions.
cshRNA target prediction algorithm
A web based graphical user interface for the identification of target sites and generation of complete cshRNA designs is available at: http://w3.biosci.utexas.edu/sullivanlab/cshRNA. Source code is available at: https://github.com/rpkincaid/cshRNA.
Northern blotting
HEK293T cells (6-well format; ~70% confluent) were transfected with 1-ug of cshRNA expression vectors using Lipofectamine 2000 (Invitrogen). Forty-eight hours post transfection, RNA was isolated using PIG-B (19) . Northern blot analysis was performed as described in (20, 21) . Briefly, 15-ug of RNA was fractionated on 15% PAGE-UREA gel and transferred to Amersham Hybond -N+ membrane (GE Healthcare). The membrane was then probed in ExpressHyb hybridization solution (Clontech, CA) with a pool of indicated DNA oligos (Integrated DNA technologies; Supplemental Table 1 ) radio-labeled with [γ-32P]-ATP (6000 Ci/mmol) by T4 polynucleotide kinase (New England Biolabs). Membranes were exposed to a storage phosphor screen (GE Healthcare) and visualized with a Typhoon biomolecular imager (GE Healthcare). Membranes were stripped by incubation in boiling 0.1% SDS with agitation for five minutes.
RISC reporter assays
HEK293T cells (24-well format, 70% confluent) were co-transfected with 500-ng/well of either pIDTSmart-kan (pISK-EV) or each cshRNA vector and 2.5-ng/well of the firefly luciferase expression vector (pcDNA3.1dsLuc2CP) and 2.5-ng/well of each individual Rluc RISC reporter using 2-ul of lipofectamine 2000/well. Forty-eight hours post-transfection, lysates were harvested and dual luciferase assay was performed on a Luminoskan Ascent Luminometer (Thermo Electronic). Raw Renilla/firefly ratios were normalized to pISK-EV and Rluc vector 3´-UTR for each data set. For each experimental replicate, transfections were performed in triplicate.
Immunoblot analysis
HEK293 cells (12-well format; 60% confluent) were transfected with 1-ug of either pISK (EV) or pISK-cshRNA-p53-h8 vectors using lipofectamine 2000. Forty-eight hours post-transfection, cells were lysed in SDS solution (1% SDS, 2% β-mercaptoethanol) by boiling for ten minutes followed by one minute of vortexing (22) . Equal volumes were fractionated on 7.5% or 12.5% PAGE-SDS followed by transfer to a 0.45 um nitrocellulose membrane (Bio Rad). The membrane was probed with p53 monoclonal mouse antibody (IMGENEX: catalog #: GSC-1010) used at 1:1000 dilution, ZC3HAV1 (PARP13) rabbit polyclonal antibody (Gene Tex; catalog #: GTX120134) used at 1:5000 dilution, and α-Tubulin monoclonal mouse antibody (Sigma-Aldrich: catalog #: T6199) used at 1:10,000 dilution. Antibodies were diluted in Phosphate Buffered Saline containing 0.1% Tween 20 (PBST) and 5% BSA. After 3 washes with PBST, membranes were blotted with IRDye 800CW and IRDye 680LT secondary antibodies (LI-COR) diluted 1:10,000 in PBST with 5% BSA. Membranes were washed four times with PBST and then scanned on an Odyssey CLx infrared imaging system (LI-COR).
RNA sequencing
HEK293T cells in a 6-well format were transfected with 1-ug of an individual cshRNA vector. Fortyeight hours post-transfection, small RNAs (<70 nts) were isolated from total RNA as described in (20) and pooled. Small RNA libraries were prepared for Illumina small RNA sequencing from the pooled small RNAs using the multiplex small RNA library prep set (New England Bio Labs) and sequenced on a Illumina HiSeq 2500 and NextSeq 500 platforms (GSAF, UT Austin). Adapter sequences were trimmed from the reads using fastx clipper from the FASTX-Toolkit software (http://hannonlab.cshl.edu/fastx_toolkit). The preprocessed reads were then mapped to cshRNA reference sequences using SHRiMP2 software package (23) . Small RNA reads were quantitated using custom scripts.
Structural prediction
Secondary structure predictions of cshRNAs were generated using the RNA folding form on the Mfold web server (24) .
Results and Discussion
Design principles of an shRNA template based on BLV miRNA genes
We set out to develop a smaller shRNA expression system by imitating the design principles of the BLV miRNA gene architecture ( Figure 1A ). To engineer shRNAs that utilize similar features of the BLV pre-miRNAs, we chose BLV-pre-miR-B1 as the archetype because it is readily transcribed by RNAP III, is efficiently processed by Dicer, and generates a highly dominant 3p derivative ( Figure 1B ) (12, 13) . We used the position of the 3p arm of BLV-pre-miR-B1 to serve as the siRNA template. To allow for variation of the siRNA template while still maintaining efficient transcription and shRNA structure, we restricted the siRNA sequences to those whose sequence complement (permitting G-U wobble pairing) conserves the minimal consensus nucleotides within A-box-1 on the 5p arm (nucleotides: 1,2,9,10,11; Figure 1C ). We also conserved siRNA nucleotides 21-23 (TCT), which are part of the termination signal, to ensure proper transcription termination to generate the 2-nt overhang. We permitted variation of the remaining nucleotides in the siRNA. These parameters give rise to permissible variable siRNAs with the following sequences: 5'-YYNNNNNNYYRNNNNNNNNNUCU-3' (Y = C/U, R = A/G, N = A/U/G/C).
To test the efficacy of this design, we searched for sequences perfectly complementary to nucleotides 1-20 of the siRNA template (5'-NNNNNNNNNYRRNNNNNNRR-3') in three different sequences: the 3'
UTR of RB1, the 3'UTR of TP53 and the entire mRNA of ZC3HAV1 (PARP13). In order increase the number of possible cshRNA targets/transcript, we did not require complementarity between nucleotides 21-23 of the siRNA and the target mRNA. We note that base pairing between the 3'-end of siRNAs and target mRNAs is not required for mRNA recognition, translational repression, or Ago2 slicer activity (25, 26) . Using these parameters, numerous sites complementary to the siRNA template were identified in each transcript ( Supplementary Table S2 ), demonstrating that target sequences amenable to our cshRNA design constraints frequently occur in diverse target sequences. Permissible target sequences in each transcript were assigned arbitrary identification numbers (e.g. cshRNA-target-h1). We selected 27 total cshRNA targets (8 targeting the p53 3'UTR, 4 targeting the RB 3'UTR, and 15 targeting the PARP13 mRNA) for analysis.
To make the cshRNA-expressing cassettes, we selected complementary siRNAs and designed the corresponding 5p arms containing the consensus nucleotides of the A-box elements ( Figure 1C ). For some constructs (the p53-and RB-targeting cshRNAs), we preserved the mismatched nucleotides at positions 7 and 8 of BLV-pre-miR-B1 that result in a predicted symmetrical "bulge" in the stem of shRNA hairpin. However, for the PARP13-targeting cshRNAs, this mismatch design element was omitted. In all cshRNAs, we maintained the predicted single asymmetric nucleotide bulge of the BLV-B1 pre-miRNA hairpin by not allowing a complementary nucleotide for position 17 of the siRNA ( Figure   1C ). For all constructs we also conserved the A in the 5p arm that is complementary to the U at siRNA position 21. The rationale for this was two-fold: 1) It preserves the 2-nt 3' overhang of the shRNA, and 2)
It provides the purine in the pyrimidine/purine junction (-1/+1) that guides the position of RNAP III transcription initiation at the 5'-end of the shRNA. The siRNA and corresponding 5p arm were then inserted into the BLV-pre-miR-B1 hairpin in place of the BLV-pre-miR 5p and 3p arms. The predicted secondary structure of the cshRNAs we chose for analysis largely maintained the structure of BLV-pre-miR-B1 (Figure 2A -D), indicating that Dicer-mediated processing of the shRNAs would likely be preserved.
BLV-based shRNA templates generate specifically processed and RISC-active siRNAs
To assess cshRNA expression and biogenesis, we made cshRNA expression vectors by replacing the BLV-pre-miR-B1 hairpin with each cshRNA in the pBLV-B1 vector, which contains 130 bps of the BLV-miR-B1 locus in a plasmid that lacks a known mammalian promoter (pIDTSmart-kan) (13) . These Figure 3A -C). These data demonstrate that our cshRNA design strategy is effective at generating shRNAs that produce small RNAs with diverse sequences.
We performed Illumina high-throughput small RNA sequencing (RNA-seq) to precisely determine the sequence of the small RNA derivatives from our cshRNA constructs. All the p53-targeting cshRNAs generated small RNAs that map to the 5p and/or 3p arms of their respective cshRNA. The majority (5/8) produced dominant 3p siRNAs ( Figure 4A ). CshRNA-p53-h5 produced co-dominant 5p and 3p
derivatives. CshRNAs p53-h1 and p53-h4 produced dominant 5p derivatives, likely accounting for the lack of observable 3p siRNAs by northern blot analysis ( Figure 3A) . Importantly, the most abundant siRNA isoform for approximately half of the constructs had the intended single predominant 5' and 3'
termini ( Figure 4A ). Three of the four RB-targeting cshRNAs produced dominant 3p siRNAs, while cshRNA-RB-h1 produced co-dominant 5p and 3p derivatives ( Figure 4B ). All the RB-targeting cshRNAs generated siRNAs with the correct 5'-end for the most abundant isoform. We did not obtain small RNA reads mapping to cshRNA-PARP13-h9, which is consistent with our northern blot analysis ( Figure 3C ).
However, cshRNA-PARP13-h9 does express an shRNA precursor ( Figure 3C ). This suggests that Dicer may not efficiently process cshRNA-PARP13-h9 precursor RNA into siRNAs. All the other PARP13targeting cshRNA constructs (14/15) generated small RNAs that map to the 5p and/or 3p arms of the pre-miRNA ( Figure 4C ). PARP13-targeting cshRNAs h5, h6, h7, h8, h10, h11, h16, h17, h19, and h28 all produced dominant 3p siRNAs, whereas cshRNAs h15, h19, h22, h23, and h29 generated co-dominant levels of 3p and 5p arms. Small RNA reads mapping to PARP13-targeting cshRNAs 22 and 23 were low, likely accounting for the lack of observable small RNAs by northern blot analysis. We observed abundant total reads of the 3p arms generated from PARP13-targeting cshRNAs h5, h8, h10, h15, h16, h17, h19, and h28, suggesting these cshRNAs are efficiently transcribed, processed, and loaded into Argonaute.
Importantly, the most abundant 3p arm isoform generated from the majority of PARP13-targeting cshRNAs had the correct intended 5' and 3' termini. These data indicate that most cshRNAs generate siRNAs of the intended sequence, a desirable feature for minimizing off-targeting effects.
We next assayed whether cshRNA-generated small RNAs are active in RISC. We engineered luciferasebased RISC reporters for the cshRNA-pRb-3, cshRNA-p53-8, and cshRNA-p53-9 by inserting two perfectly complementary sequences to either the 5p or 3p arms of each cshRNA into the 3'-UTR of Renilla luciferase ( Figure 5A ). For the PARP13-targeting cshRNAs, we engineered similar reporters for the siRNA (3p arm). Co-expression of cshRNA-Rb-h3 resulted in a significant reduction (~80%) of luciferase activity of the 3p reporter, but had no effect on the 5p reporter ( Figure 5B ). Similar results were observed for cshRNA-p53-h8 ( Figure 5C ). CshRNA-p53-h9 repressed both the 5p and 3p reporters ( Figure 5D ), indicating that cshRNA-p53-h9 produces co-dominant siRNAs, consistent with the abundant read counts of both the 5p and 3p derivatives in our RNA-seq analysis (Figure 4 ). The majority (11/14) of PARP13-targeting cshRNAs reduced Rluc expression from their respective RISC reporters by greater than 50%, with six decreasing Rluc expression by over 80% ( Figure 5E ). These data demonstrate that cshRNAs generate RISC-active siRNAs.
To assay whether cshRNA-generated siRNAs can repress their intended target within the context of a longer natural 3' UTR, we inserted the entire 3' UTRs of the p53 and RB mRNAs downstream of Renilla luciferase in pcDNA3.1dsRluc and evaluated the ability of the corresponding cshRNAs to repress Rluc expression ( Figure 6A ). All four of the RB-targeting cshRNAs decreased Rluc-RB-3'-UTR expression, with cshRNA-RB-h3 reducing Rluc-pRB-3'-UTR expression to the largest degree (80% reduction; Figure   6B ). Roughly half of the p53-targeting cshRNAs (h6, h7, h8, and h9) repressed Rluc-p53-3'-UTR, with cshRNA-p53-h8 reducing expression by 80% ( Figure 6C ). To determine if cshRNAs are able to knockdown endogenous target proteins, we evaluated p53 and PARP13 levels in cells transiently expressing either cshRNA-p53-h8 or any of several different PARP13-targeting cshRNAs (h7, h8, h11, h19). Both cshRNA-p53-h8 and cshRNA-PARP13-h19 significantly reduced p53 and PARP13 levels, respectively ( Figure 6D ,E). Combined, these results demonstrate that cshRNAs can knockdown gene expression of their intended target mRNA transcript.
The cshRNA coding space can be reduced to 100 base pairs
To determine if we could reduce the template space required for cshRNA expression, we tested whether we could eliminate sequence from the 5' flanking region of BLV-miR-B1 locus or select cshRNAs.
Although some RNAP III type II promoters contain a functional upstream TATA box at approximately position -30 (16, 17) , the BLV-miR-B1 locus and our cshRNA vectors lack this cis element, indicating the upstream sequence may not be important for RNAP III transcription initiation. Therefore, we made vectors in which we truncated 15-or 30-bps from the 5'-end of the upstream of BLV-pre-miR-B1/cshRNA in the pBLV-B1, cshRNA-p53-h8, and cshRNA-PARP13-h19 vectors ( Figure 7A ). Northern blot analysis revealed that deletions of this region did not markedly reduce expression of BLV-miR-B1 or the cshRNA-generated siRNAs (Figure 7B,C) . Thus, small RNAs can be efficiently expressed from a 100 bp gene expression cassette that includes the 56-bp cshRNA, 31 bps downstream, and only 13 bp of upstream BLV-pre-miR-B1 sequence.
Algorithm for easy and flexible design of cshRNA templates
We generated a computational design tool for cshRNA expression cassettes. The web-based interface program is available at http://w3.biosci.utexas.edu/sullivanlab/cshRNA. Source code is available at https://github.com/rpkincaid/cshRNA. The default setting generates the 100-bp template shown in Figure   7D , but there is an optional parameter that can incorporate the additional 30-bp sequence upstream of BLV-pre-miR-B1 (add 5' flanking sequence). Although not supported by the vectors we tested ( Figure   7A -C), its plausible that additional BLV 5' cis elements may improve expression of some cshRNAs. To simplify the cshRNA design, we omitted the requirement to mismatch nucleotides at positions 7 and 8
( Figure 7D ), as this was not required for the biogenesis of the PARP13-targeting cshRNAs (Figures 2-4) .
The default setting maximizes the number of possible cshRNA targets/transcript by using the least stringent yet still permissible siRNA template. However, the program includes several optional design parameters that restrict the siRNA template to potentially optimize cshRNA effectiveness. These optional parameters include: i) Conservation of the consensus thymidine in A-box-2 [complementary to siRNA position 3 ( Figure 7D) ], which may provide more robust and/or consistent shRNA expression (13), though it was not absolutely required for cshRNA expression (e.g. cshRNA-p53-h8). ii) The requirement for the siRNA to contain a 5'-uracil. This appeared to promote more efficient and more precise siRNA biogenesis (Figure 3 ), which is consistent with studies demonstrating a 5'-U promotes Dicer processing and Argonaute association (27, 28) . iii) The requirement for nucleotides 21-23 of the siRNA to be perfectly complementary to the target mRNA. Although not absolutely required for cshRNA-mediated knockdown of gene expression [e.g. shRNA-p53-h8 and cshRNA-PARP13-h19 ( Figure 6D ,E)], this may increase knockdown efficiency due to more efficient Ago2 slicer activity in some contexts (25, 26) . We note that selecting this option substantially decreases the number of possible cshRNA targets/transcript.
Finally, we included the option of excluding cshRNAs with internal termination signal-like sequences and repetitive sequences, which are likely problematic to effective cshRNA generation. Combined, these features provide flexibility in cshRNA design that allows for modulation of cshRNA biogenesis/effectiveness while maximizing potential target sequences.
Conclusions
Most of the cshRNA cassettes we tested generated RISC-active siRNAs (Figure 3-6 ). However, a small fraction of the cshRNAs did not generate abundant siRNAs. It is likely that variability in the A-box promoter elements and variability in shRNA structure and processing account for this. Therefore, for routine laboratory purposes where template size is not an issue, U6/H1-driven shRNAs may be preferable to cshRNAs. In addition, not all RISC-active cshRNA-generated siRNAs reduced gene expression of their target mRNA ( Figure 6 ). This is likely a consequence of inaccessibility of the mRNA target sequence to RISC. Therefore, cshRNA effectiveness could be enhanced by combining our design program with existing siRNA target accessibility prediction programs (29) .
Reducing the coding space required for small RNA expression may be especially useful for therapeutic applications. Recently, Mefferd et al. (2015) used the biogenesis mechanisms of the mouse γ-herpesvirus 68 (MHV68) miRNAs to develop CRISPR/Cas9 single guide RNAs (sgRNAs) expressed by tRNA promoters (RNAP III type II) to facilitate AAV-based Cas9/sgRNA vectors (30) (31) (32) (33) (34) (35) . In a similar manner, our BLV-based cshRNA expression system uses RNAP III type II promoters to drive shRNA expression.
This requires less than half of the space of U6/H1-driven shRNA cassettes. We envision that cshRNAs may be useful for small payload gene therapy vectors that express multiple shRNAs or combinations of protein coding genes and shRNAs. Such vectors include supercoiled minicircle DNA vectors, which can be only a few hundred nucleotides of total size, and AAV vectors which have less than 5 kilobases of payload capacity (36) (37) (38) (39) (40) (41) (42) (43) (44) . In summary, our BLV-based cshRNA template reduces the amount of coding sequence required for shRNA expression, and may offer other benefits in terms of amount of expression and specific shRNA processing. cshRNAs show promise as a tool for future therapeutic RNAi applications. 
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